Interview: June Raine and the rise of pharmacovigilance and risk management
This article was originally published in SRA
Executive Summary
Barely three years old, the Pharmacovigilance Risk Assessment Committee is the European Medicine Agency's new kid on the block. The PRAC, according to its chair Dr June Raine, is a "clear voice for public health" that will only get louder as companies and regulators increasingly focus on providing earlier access to medicines and demand for real life data grows. Dr Raine talks to Scrip Regulatory Affairs about the PRAC's role in risk management, adaptive pathways, data gathering and the voice of the patient.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.